Monitor for future filings that provide revenue or contract wins from the defense portfolio, and watch for NYSE American compliance updates. The stock's micro-cap status and going-concern risk warrant caution; any material financial disclosure would be a significant catalyst.
Price Chart
Executive Summary
BiomX filed an 8-K posting an updated investor presentation detailing its completed strategic transition from clinical-stage biotech to a defense and security technology holding company. The presentation describes its portfolio (Zorronet AI C5ISR platform and DFSL LADAR detection), leadership, and growth strategy but provides no financial data, revenue, or guidance. This is a routine informational update with no material new financial information.
Key Facts
- BiomX has completed its strategic transition from clinical-stage biotech to a defense and security technology holding company.
- The portfolio includes Zorronet (AI-powered Autonomous Command Center platform, 100% owned) and DFSL (LADAR-based threat detection, 60% owned).
- The presentation highlights leadership with experience from Mossad, Elbit Systems, and IDF, and an advisory board including a former Deputy Head of the Mossad.
- The company acknowledges a going-concern qualification in its financial statements and is focused on implementing its NYSE American compliance plan.
- No financial data, revenue, earnings, or guidance were provided in this filing.
Financial Impact
No financial figures disclosed; filing is qualitative and forward-looking.
Risk Factors
- Going-concern qualification in financial statements indicates substantial doubt about ability to continue as a going concern.
- Risk of delisting from NYSE American if compliance plan is not executed.
- Customer concentration with reliance on a limited number of key relationships (Elbit Systems, Rafael).
- Need for additional capital to fund operations and growth strategy.
- Geopolitical risks related to Israeli operations and export control laws.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-069911 |
| Document: ea0295251-8k_biomx.htm | 0001213900-26-069911 |
| Document: ea029525101ex99-1.htm | 0001213900-26-069911 |
| Document: 0001213900-26-069911-index-headers.html | 0001213900-26-069911 |
| Document: 0001213900-26-069911-index.html | 0001213900-26-069911 |
| Document: 0001213900-26-069911.txt | 0001213900-26-069911 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.1425 $1.85 | ▲ +1198.25% | ▲ +1199.20% | $0.3600 (+152.63%) |
Aug 28, 2026 5w ago | 8-K | $0.1371 $0.1550 | ▲ +13.06% | ▲ +13.20% | $0.3600 (+162.58%) |
Aug 5, 2026 8w ago | Press Release | $0.1800 $0.1483 | ▲ +17.61% | ▲ +17.96% | $0.3600 (−100.00%) |
Jul 28, 2026 9w ago | 8-K | $0.1834 $0.1868 | ▼ −1.85% | ▲ +0.42% | $0.3600 (−96.29%) |
Jul 28, 2026 9w ago | Press Release | $0.1834 $0.1868 | ▼ −1.85% | ▲ +0.42% | $0.3600 (−96.29%) |
Jul 27, 2026 9w ago | 424B5 | $0.1834 $0.1868 | ▼ −1.85% | ▲ +0.42% | $0.3600 (−96.29%) |
Jul 8, 2026 12w ago | Press Release | $0.2758 $0.2100 | ▼ −23.86% | ▼ −24.72% | $0.3600 (+30.53%) |
Jul 2, 2026 13w ago | 8-K | $0.3190 $0.2800 | ▲ +12.23% | ▲ +13.16% | $0.3600 (−12.85%) |
Jun 29, 2026 13w ago | S-1 | $0.3478 $0.3020 | ▲ +13.17% | ▲ +13.77% | $0.3600 (−3.51%) |
Jun 22, 2026 14w ago | DEFA14A | $0.4615 $0.3590 | ▼ −22.21% | ▼ −23.22% | $0.3600 (−21.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access